Thomas Cerny

4.2k total citations · 1 hit paper
52 papers, 2.7k citations indexed

About

Thomas Cerny is a scholar working on Oncology, Pathology and Forensic Medicine and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Thomas Cerny has authored 52 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 16 papers in Pathology and Forensic Medicine and 16 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Thomas Cerny's work include Lymphoma Diagnosis and Treatment (15 papers), Lung Cancer Treatments and Mutations (12 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Thomas Cerny is often cited by papers focused on Lymphoma Diagnosis and Treatment (15 papers), Lung Cancer Treatments and Mutations (12 papers) and Chronic Lymphocytic Leukemia Research (6 papers). Thomas Cerny collaborates with scholars based in Switzerland, Italy and United States. Thomas Cerny's co-authors include Rolf A. Stahel, C. Herrmann, Harald Frick, Aurelius Omlin, Sabine Schmid, Karl Heinimann, Martino Introna, Andrea L. Rose, Bettina Borisch and Peter Johnson and has published in prestigious journals such as Journal of Clinical Oncology, Blood and PLoS ONE.

In The Last Decade

Thomas Cerny

51 papers receiving 2.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Multiple primary tumours: challenges and approaches, a review

2017 342 citations Harald Frick, C. Herrmann et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Thomas Cerny Switzerland	23	1.2k	929	757	453	391	52	2.7k
James D. Bearden United States	31	1.7k 1.4×	888 1.0×	452 0.6×	252 0.6×	304 0.8×	94	3.1k
Laura Giordano Italy	31	982 0.8×	873 0.9×	519 0.7×	318 0.7×	387 1.0×	165	3.3k
Glenn Mills United States	26	1.9k 1.6×	930 1.0×	570 0.8×	220 0.5×	673 1.7×	119	3.4k
Samuel A. Jacobs United States	25	1.4k 1.2×	450 0.5×	753 1.0×	163 0.4×	620 1.6×	143	2.9k
Sercan Aksoy Türkiye	27	1.7k 1.5×	780 0.8×	334 0.4×	350 0.8×	554 1.4×	284	3.6k
Ellen G. Feigal United States	21	1.5k 1.3×	379 0.4×	478 0.6×	477 1.1×	735 1.9×	43	2.8k
Lingyun Ji United States	34	944 0.8×	720 0.8×	366 0.5×	260 0.6×	828 2.1×	130	3.5k
Michael Huncharek United States	32	810 0.7×	964 1.0×	289 0.4×	350 0.8×	468 1.2×	74	3.1k
Alex McMillan United States	33	944 0.8×	712 0.8×	542 0.7×	290 0.6×	861 2.2×	57	3.5k
Kadri Altundağ Türkiye	30	2.5k 2.1×	915 1.0×	339 0.4×	281 0.6×	717 1.8×	251	3.9k

Countries citing papers authored by Thomas Cerny

Since Specialization

Citations

This map shows the geographic impact of Thomas Cerny's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas Cerny with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas Cerny more than expected).

Fields of papers citing papers by Thomas Cerny

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas Cerny. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas Cerny. The network helps show where Thomas Cerny may publish in the future.

Co-authorship network of co-authors of Thomas Cerny

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas Cerny. A scholar is included among the top collaborators of Thomas Cerny based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas Cerny. Thomas Cerny is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Menges, Dominik, Aurelius Omlin, Richard Cathomas, et al.. (2023). Patient and General Population Preferences Regarding the Benefits and Harms of Treatment for Metastatic Prostate Cancer: A Discrete Choice Experiment. European Urology Open Science. 51. 26–38. 4 indexed citations

Menges, Dominik, et al.. (2022). Patient Preference Studies for Advanced Prostate Cancer Treatment Along the Medical Product Life Cycle: Systematic Literature Review. Patient Preference and Adherence. Volume 16. 1539–1557. 4 indexed citations

Hitz, Felicitas, Karin Ribi, Qiyu Li, et al.. (2013). Predictors of satisfaction with treatment decision, decision-making preferences, and main treatment goals in patients with advanced cancer. Supportive Care in Cancer. 21(11). 3085–3093. 21 indexed citations

Herrmann, C., Thomas Cerny, Penelope Vounatsou, et al.. (2013). Cancer survivors in Switzerland: a rapidly growing population to care for. BMC Cancer. 13(1). 287–287. 26 indexed citations

Ess, S.M., Harish C. Phuleria, Martin Früh, et al.. (2013). Bayesian spatio-temporal modelling of tobacco-related cancer mortality in Switzerland. Geospatial health. 7(2). 219–219. 8 indexed citations

Martinelli, Giovanni, Shu-Fang Hsu Schmitz, Thomas Cerny, et al.. (2010). Long-Term Follow-Up of Patients With Follicular Lymphoma Receiving Single-Agent Rituximab at Two Different Schedules in Trial SAKK 35/98. Journal of Clinical Oncology. 28(29). 4480–4484. 168 indexed citations

Cerny, Thomas, et al.. (2009). Lung Cancer in the Canton of St. Gallen, Eastern Switzerland: Sex-Associated Differences in Smoking Habits, Disease Presentation and Survival. Onkologie. 32(10). 569–573. 6 indexed citations

Lanz, Christian, Martin Früh, Wolfgang Thormann, Thomas Cerny, & Bernhard H. Lauterburg. (2007). Rapid determination of gemcitabine in plasma and serum using reversed‐phase HPLC. Journal of Separation Science. 30(12). 1811–1820. 36 indexed citations

Sessa, Cristiana, Sara Cresta, Thomas Cerny, et al.. (2006). Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors. Annals of Oncology. 18(3). 561–568. 21 indexed citations

10.

Betticher, Daniel, Giovanni Martinelli, John Radford, et al.. (2006). Sequential high dose chemotherapy as initial treatment for aggressive sub-types of Non-Hodgkin Lymphoma: results of the international randomized phase III trial (MISTRAL). Annals of Oncology. 17(10). 1546–1552. 34 indexed citations

11.

Ghielmini, Michele, Kaspar Rufibach, Gilles Salles, et al.. (2005). Single agent rituximab in patients with follicular or mantle cell lymphoma: clinical and biological factors that are predictive of response and event-free survival as well as the effect of rituximab on the immune system: a study of the Swiss Group for Clinical Cancer Research (SAKK). Annals of Oncology. 16(10). 1675–1682. 121 indexed citations

12.

Ravaud, Alain, Thomas Cerny, C. Terret, et al.. (2005). Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3weeks in solid tumours: An ECSG/EORTC study. European Journal of Cancer. 41(5). 702–707. 80 indexed citations

13.

Henz, Samuel, Hans Peter Schmid, Walter F. Riesen, et al.. (2005). Hypertriglyceridemia as a possible risk factor for prostate cancer. Prostate Cancer and Prostatic Diseases. 8(4). 316–320. 66 indexed citations

14.

Cerny, Thomas & Silke Gillessen. (2002). Advances in the treatment of non-Hodgkin's lymphoma. Annals of Oncology. 13. 211–216. 7 indexed citations

15.

Cerny, Thomas, Bettina Borisch, Martino Introna, Peter Johnson, & Andrea L. Rose. (2002). Mechanism of action of rituximab. Anti-Cancer Drugs. 13. S3–S10. 199 indexed citations

16.

DʼAddario, Giannicola, J. Torhorst, Rudolf Maibach, et al.. (2002). HIV-testing and Newly-diagnosed Malignant Lymphomas. The SAKK 96/90 Registration Study. Leukemia & lymphoma. 44(1). 133–138. 2 indexed citations

17.

Pichert, Gabriella, Shu-Fang Hsu Schmitz, U Hess, et al.. (2001). Weekly x 4 Induction Therapy with the Anti-CD20 Antibody Rituximab: Effect on Circulating t(14;18)+ Follicular Lymphoma Cells. Clinical Lymphoma. 1(4). 293–297. 5 indexed citations

18.

Pampallona, S., et al.. (2000). Attitudes and Beliefs towards Disease and Treatment in Patients with Advanced Cancer Using Anthroposophical Medicine. Oncology Research and Treatment. 23(6). 558–563. 20 indexed citations

19.

Korte, Wolfgang, et al.. (1999). Accelerated progression of multiple myeloma during anti-CD20 (Rituximab) therapy. Annals of Oncology. 10(10). 1249–1250. 12 indexed citations

20.

Cerny, Thomas, Steven Kaplan, N. Pavlidis, et al.. (1994). Docetaxel (TaxotereTM) is active in non-small-cell lung cancer: a phase II trial of the EORTC early clinical trials group (ECTG). British Journal of Cancer. 70(2). 384–387. 145 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact